RNS Number : 3870X
ValiRx PLC
28 August 2020


("ValiRx", the "Company" or the "Group")

Exercise of Warrants


London, UK 28 August 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces  it has received notification for the exercise of a warrant over 250,000  ordinary shares in the Company at an exercise price of 12.5 pence per share providing the Company with proceeds of £31,250 ("Warrant Exercise").


The Company has also received notifications for the exercise of warrants pursuant to the Fundraise Warrants announced on 4 May 2020 in relation to the fundraise at the time. The Company has received, in aggregate, exercise of warrants over 2,791,666 ordinary shares at an exercise price of 13 pence per share providing the Company with aggregate proceeds of £362,916. The Company has previously applied to list these shares as part of the block listing of 9,034,734 ordinary shares of 0.1 pence each in the Company (announced on 19 August 2020), which were admitted to trading on AIM on 24 August 2020.


Application will be made to the London Stock Exchange to admit the 250,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 September 2020.  The new ordinary shares will rank pari passu with the existing ordinary shares.


For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise and the exercise of 2,791,666  warrants pursuant to the ValiRx plc Fundraise Warrants May 2020 block listing application announced on 19 August 2020, the enlarged issued share capital of the Company will comprise 57,104,039 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.


A Total Voting Rights announcement will be released by the Company on 1 September 2020.


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information please contact:

ValiRx plc

Tel: +44 (0) 20 7073 2628

Suzanne Dilly


Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880


Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker


Tel: +44 (0) 20 7469 0930









This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.